Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Descrição
FDA approves Dupixent as first biologic medicine for children aged
PDF) Dupilumab provides favourable long-term safety and efficacy
Developments in the Management of Severe Asthma in Children and
Long-Term Efficacy and Safety of Dupilumab in Adolescents with
Dupilumab efficacy in children with uncontrolled, moderate-to
Dupilumab efficacy in children with uncontrolled type 2 asthma
JCM, Free Full-Text
Dupilumab leads to better-controlled asthma and quality of life in
Dupilumab in children aged 6 months to younger than 6 years with
Dupilumab add-on therapy decreases exacerbations in moderate-to
Dupilumab May Improve Lung Function in Children Age 6-11 with
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
